Navigation Links
The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies
Date:7/21/2014

BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, owing largely to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment. In 2023, these novel premium-priced agents—which include the anti-beta-amyloid monoclonal antibodies solanezumab (Eli Lilly) and gantenerumab (Roche), as well as the BACE inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn sales of $7 billion combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Other key findings from the Pharmacor report entitled Alzheimer's Disease:

  • A new symptomatic alternative: Lundbeck/Otsuka's novel 5HT-6 receptor antagonist, Lu-AE58054, will launch as an adjunctive symptomatic treatment for AD and achieve blockbuster sales within the forecast period, capturing nearly 10 percent of major-market sales in 2023.
  • Population growth: The surging prevalence of AD as the population ages will drive growth across the major markets. We also expect diagnosis and drug-treatment rates to rise modestly in the pre-AD 1-2 years* and mild AD patient segments as DMTs and new diagnostic technologies gradually gain traction.
  • Current agents stay relevant: Today's clinical mainstays deliver modest symptomatic efficacy and do not affect disease progression but will remain the foundation of treatment throughout the forecast period—aided in part by growing generic availability. We forecast that acetylcholinesterase inhibitors (AChEIs) will continue to capture over 70 percent total patient share (across all AD subpopulations) in 2023, while NMDA receptor antagonist products, including Forest's Namenda/Namenda XR, will continue to capture approximately 35 percent patient share.

Comments from Decision Resources Group Analyst Alana Simorellis, Ph.D.:

  • "The projected launch of Eli Lilly's solanezumab, potentially the first ever DMT approved for the treatment of AD, will be a transformative event affecting the AD market as early as 2018. Commensurate with ongoing development and the views of experts in the field, we expect that future DMTs will most likely see the greatest uptake in the pre-AD and mild AD populations. Moreover, experts interviewed note that new symptomatic options also are sorely needed. Lundbeck/Otsuka's Lu-AE58054 and potentially others could partially address this need beginning in 2017."
  • "While AD drug development is understandably focused on disease modification, there exists an important area of additional unmet need for safer, more-effective symptomatic therapies that can control the behavior disturbances associated with later-stage AD. Development in this arena is underway, with clinical trials assessing promising agents like Lundbeck/Otsuka's brexpiprazole for AD-associated agitation."

*Decision Resources Group defines its proprietary pre-AD 1-2 years population as those patients who will go on to develop AD within the next one to two years.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
2. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
3. New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimers Disease
4. New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimers Disease
5. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
6. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
7. Pain Management Medical Journal Features BioElectronics Innovative Pain Products Because Pain is Not a Druggable Disease
8. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
9. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
10. Asleep During Brain Surgery: A Comfortable Alternative for Patients with Parkinsons Disease
11. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/9/2017)... 9, 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders ... design, manufacture, sale and distribution of the AeroForm® Tissue ... of its commercial roll-out in the United ... than one hundred (100) medical institutions and health systems, ... a needle-free alternative for women who choose reconstructive surgery ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ ... Bayfront and Erie Convention Center on June 8-10. The weekend consisted of ... bowl, award and scholarship presentations, and professional networking. , On Friday June ...
(Date:6/24/2017)... TX (PRWEB) , ... June 24, 2017 , ... The ... to spend time outdoors. Home and business owners should be aware that the summer ... the lake. In fact, mechanical locks and keys can be negatively affected from direct ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Network today announced the launch of Care Management Alerts and Dashboards, an innovative ... patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for ... consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work as ... of all charities reviewed by Charity Navigator and earns ANRF a spot on their ...
(Date:6/23/2017)... ... , ... Studies show evidence that carotenoids and antioxidants derived either from the ... patients. , But how often do ophthalmologists and optometrists in Sweden recommend the use ... or with early symptoms of AMD? A study published recently in Dove ...
Breaking Medicine News(10 mins):